2000–2010 to 2011–2022 saw increase in lifetime risk for atrial fibrillation
From 2000 to 2022, there was an increase in the lifetime risk for atrial fibrillation, according to a study published online April 17 in The BMJ.
Apr 22, 2024
0
0
From 2000 to 2022, there was an increase in the lifetime risk for atrial fibrillation, according to a study published online April 17 in The BMJ.
Apr 22, 2024
0
0
A new guideline from the American College of Physicians (ACP) offers clinical recommendations for the use of newer pharmacological treatments of adults with type 2 diabetes. This is an update of ACP's 2017 guideline and is ...
Apr 19, 2024
0
4
Heart failure (HF) after myocardial infarction (MI) is a global health issue with a high mortality rate. Multiple molecular mechanisms are involved in the development of HF after MI. However, interventions targeting these ...
Apr 18, 2024
0
10
Myocardial infarction, more commonly known as a heart attack, is a leading cause of death worldwide. Biomarkers called plasma metabolites may play a key role in the physiological pathways involved in myocardial infarctions. ...
Apr 17, 2024
0
4
Referring people to a specialized rehabilitation program following a cardiac incident could reduce the chance they will be readmitted to hospital and potentially lower their risk of death, according to new Flinders University ...
Apr 11, 2024
0
0
A new meta-analysis shows sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular events in patients with either diabetes at high risk of atherosclerotic cardiovascular disease (ASCVD), ...
Apr 8, 2024
0
0
About 800,000 people in the U.S. suffer a heart attack every year, and about 30% of them will go on to develop heart failure. There are limited treatments to prevent or slow that development.
Apr 8, 2024
0
0
For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the ...
Apr 8, 2024
0
0
While the composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
Apr 8, 2024
0
0
Findings from a new study by public health researchers at the U of A suggest that people older than 50 might want to consult a doctor before taking up pickleball, the tennis-like sport that has grown in popularity over the ...
Apr 5, 2024
0
22
Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack, results from the interruption of blood supply to a part of the heart, causing heart cells to die. This is most commonly due to occlusion (blockage) of a coronary artery following the rupture of a vulnerable atherosclerotic plaque, which is an unstable collection of lipids (cholesterol and fatty acids) and white blood cells (especially macrophages) in the wall of an artery. The resulting ischemia (restriction in blood supply) and ensuing oxygen shortage, if left untreated for a sufficient period of time, can cause damage or death (infarction) of heart muscle tissue (myocardium).
Classical symptoms of acute myocardial infarction include sudden chest pain (typically radiating to the left arm or left side of the neck), shortness of breath, nausea, vomiting, palpitations, sweating, and anxiety (often described as a sense of impending doom). Women may experience fewer typical symptoms than men, most commonly shortness of breath, weakness, a feeling of indigestion, and fatigue. Approximately one-quarter of all myocardial infarctions are "silent", that is without chest pain or other symptoms.
Among the diagnostic tests available to detect heart muscle damage are an electrocardiogram (ECG), echocardiography, cardiac MRI and various blood tests. The most often used blood markers are the creatine kinase-MB (CK-MB) fraction and the troponin levels. Immediate treatment for suspected acute myocardial infarction includes oxygen, aspirin, and sublingual nitroglycerin.
Most cases of STEMI (ST elevation MI) are treated with thrombolysis or percutaneous coronary intervention (PCI). NSTEMI (non-ST elevation MI) should be managed with medication, although PCI is often performed during hospital admission. In people who have multiple blockages and who are relatively stable, or in a few emergency cases, bypass surgery may be an option, especially in diabetics.
Heart attacks are the leading cause of death for both men and women worldwide. Important risk factors are previous cardiovascular disease, older age, tobacco smoking, high blood levels of certain lipids (triglycerides, low-density lipoprotein) and low levels of high density lipoprotein (HDL), diabetes, high blood pressure, obesity, chronic kidney disease, heart failure, excessive alcohol consumption, the abuse of certain drugs (such as cocaine and methamphetamine), and chronic high stress levels.
This text uses material from Wikipedia licensed under CC BY-SA